CTRI/2025/01/079095进行中（未招募）Unknown
A Prospective, Open-label, Non-Comparative, Non-interventional, Multi-center, Active Post Marketing Surveillance (PMS) study to Assess the safety and tolerability of Diclofenac sodium 75mg/ml Injection manufactured by Themis Medicare Ltd, in patients with acute painful conditions
Themis Medicare Ltd.5 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2025年2月1日最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 200
- 试验地点
- 5
- 主要终点
- 1. Number of adverse events during the study period
研究概览
简要总结
This is a prospective, Open-label, Non-Comparative, Non-interventional, Multi-center, Active Post Marketing Surveillance (PMS) study under a structured protocol to monitor and assess safety of Diclofenac sodium 75mg/ml Injection during the real-world usage. All treatment and monitoring of the patients will be done at the discretion of the treating physician (Investigator). The study will include 200 subjects including male & female patients of greater than or equal to 18 years of age with acute painful conditions in post operative conditions.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18.00 Year(s) 至 99.00 Year(s)（—）
- 性别
- All
入选标准
- •Male and female patients of greater than or equal to 18 years of age
- •Patients requiring diclofenac injection for management of painful conditions in post-operative condition
- •Patients/LAR who agree to give informed consent.
排除标准
- •Any of the contraindications to use of the study investigational product, as per the Prescribing Information a.
- •Known hypersensitivity to the active substance or to any of the excipients b.
- •Active gastric or intestinal ulcer, bleeding or perforation c.
- •Last trimester of pregnancy d.
- •History of severe hepatic, renal or cardiac failure e.
- •Patients in whom attacks of asthma, urticaria, or acute rhinitis are precipitated by acetylsalicylic acid or other NSAIDs f.
- •Haemostasias disorders or current anticoagulant treatment (for intramuscular route of administration only) g.
- •Established congestive heart failure (NYHA II-IV), ischemic heart disease, peripheral arterial disease and/or cerebrovascular disease Specifically, for I.V. use h.
- •Concomitant NSAID or anticoagulant use (including low dose heparin).
- •History of hemorrhagic diathesis, a history of confirmed or suspected cerebrovascular bleeding j.
- •Operations associated with a high risk of hemorrhage k.
- •A history of asthma l.
- •Moderate or severe renal impairment (serum creatinine greater than 160 µmol/L) m.
- •Hypovolemia or dehydration from any cause
- •A subject who is judged by the investigator as inappropriate to participate in the study for any reason other than those mentioned above.
结局指标
主要结局
1. Number of adverse events during the study period
时间窗: 1. Number of adverse events from baseline (Day 1) to End of study (Day 3).
次要结局
- 1. Number of SAEs during the study period.(2. Incidence of all SAEs unrelated/related to study drug during the study.)
研究者
Dr Ambanna Gowda
Citizen Hospital
研究点 (5)
Loading locations...
相似试验
招募中
不适用
The Liquid Embolic Agent for the Treatment of Brain Arteriovenous MalformationArteriovenous FistulaNCT07314047MicroPort NeuroTech Co., Ltd.116
尚未招募
Unknown
To Evaluate the Safety and Performance of Mural Drug Eluting Stent .CTRI/2025/12/099358Meril Life Sciences Pvt. Ltd136
尚未招募
不适用
Efficacy and Safety of the Ultrasound Stimulation Device NEFRONIX in Patients With Chronic Kidney DiseaseChronic Kidney DiseaseNCT07339098Anasonic20
招募中
3 期
Efficacy and safety study of Bedaquiline in MB Leprosy.CTRI/2025/02/079888Janssen Pharmaceutica NV262
已完成
3 期
A clinical study to evaluate the efficacy and safety of Semaglutide Injection in patients with weight management.CTRI/2025/03/082620Zydus Lifesciences Limited282